Summary
Placeholder summary. Replace with the abstract once the manuscript is finalized. The paper covers the metabolomic signatures associated with BioTwin’s cancer detection work, the validation model construction, and the cross-gradient validation between 5min and 15min metabolomic acquisitions.
Why it matters
BioTwin’s oncology research arm operates under research-only positioning. Publishing the methodology and the evaluation results is how the platform earns the trust required for any future clinical translation.
Authors
To be confirmed.